

Supplementary Table 13: Patient information for Supplementary Figure 3

		CON	CD	UC
<b>Number</b>		10	11	6
<b>Age (Ø, range)</b>		28 (22-36)	40 (25-60)	46 (23-72)
<b>Female [%]</b>		50.0	63.6	50.0
<b>HBI (Ø, range)</b>			4.6 (0-10)	
<b>Mayo c.s. (Ø, range)</b>				1.4 (0-3)
<b>Therapy [%]</b>	<i>Aminosalisylates</i>		9.1	16.7
	<i>Steroids</i>		0.0	16.7
	<i>Immunosuppressants</i>		0.0	0.0
	<i>Anti-TNF antibodies</i>		90.9	83.3
	<i>Vedolizumab</i>		0.0	0.0
	<i>Ustekinumab</i>		9.1	0.0
<b>Disease localization [%]</b>			L1: 0.0	E1: 0.0
			L2: 0.0	E2: 33.3
			L3: 81.8	E3: 66.7
			L4: 0.0	
			L4+: 18.2	